China
Africa
Explore chapters and articles related to this topic
Major Depressive Disorder Detection and Monitoring Using Smart Wearable Devices with Multi-Feature Sensing
Published in Govind Singh Patel, Seema Nayak, Sunil Kumar Chaudhary, Machine Learning, Deep Learning, Big Data, and Internet of Things for Healthcare, 2023
Shamla Mantri, Seema Nayak, Ritom Gupta, Pranav Bakre, Pratik Gorade, Vignesh Iyer
PHQ-9 is a DSM-5 approved mental health questionnaire consisting of nine questions answered by the subject. A PHQ-9 questionnaire has a sensitivity of 88 percent and specificity of 88 percent for PHQ Scores ≥ 10, implying PHQ-9 is a reliable measure for identifying moderate and severe levels of depression [5]. The severity measures for PHQ scores are shown in Table 6.1.
Depression, Anxiety, Stress, and Spirituality in Cardiovascular Disease
Published in Stephen T. Sinatra, Mark C. Houston, Nutritional and Integrative Strategies in Cardiovascular Medicine, 2022
Erminia Guarneri, Shyamia Stone
The PHQ-9, for example, is an easy-to-use, validated tool for identifying the severity of depression. These instruments provide information about severity of depressive symptoms based upon frequency, severity, and impact on quality of life. Each of these measures simplifies DSM criteria and provides an estimated guideline of the level of depression that may include categories such as normal/not depressed, mild, borderline, moderate, and severe depression.9–12 A measure specifically for cardiac patients has been developed that also assesses specific presentations of depression that may occur after a cardiovascular incident, including concern about health and recovery, fear of impending health issues or dying, and loss of independence or function.13
Detection of Emotional Cues of Depression Due to COVID-19 Pandemic
Published in Ram Shringar Raw, Vishal Jain, Sanjoy Das, Meenakshi Sharma, Pandemic Detection and Analysis Through Smart Computing Technologies, 2022
Abhishek A. Vichare, Satishkumar Varma
The questionnaire used in the survey is based on the instruction manual of the patient health questionnaire (PHQ) along with generalized anxiety disorder (GAD-7). At first PHQ-9 was designed to determine GAD-7. Depression is assessed using the PHQ-9 [5]. GAD-7 is widely used to conduct research in anxiety disorders as well in medical practice [27].
Psychosocial factors among patients undergoing orbital exenteration
Published in Clinical and Experimental Optometry, 2023
Neelima Balakrishnan, Sahil Agrawal, Rachna Bhargava, Veena Jain, Neelam Pushker, Rachna Meel, Mandeep S. Bajaj
The PHQ-9 is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders.3 PHQ-9 is a validated questionnaire, that is often used for diagnosis of depression and monitoring response to treatment.4 This instrument has been used previously in screening for depression in cancer patients and has also been used in assessing depressive symptoms in patients with visual impairment and prosthetic eye users.5–7 It consists of nine questions with responses ranging from “0” indicating “not at all” to 3 indicating “nearly every day”. The scores range from 0 to 27 with a cut-off of ≥ 10 for diagnosis of depression with scores of 5, 10, 15, and 20 representing mild, moderate, moderately severe, and severe depression, respectively.8
Behavioral couples therapy for brain injury: single case methodology with bi-phasic design
Published in Brain Injury, 2023
Ndidi T Boakye, Kathryn M Taylor, Sarah Corrie
Secondary outcome measures included the Patient Health Questionnaire-9 items (PHQ-9) (29) and Generalized Anxiety Disorder Assessment-7 items (GAD-7) (30). The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring, and measuring the severity of depression. It incorporates DSM-IV depression diagnostic criteria along with other leading major depressive symptoms within a brief self-report tool. The GAD-7 is a self-administered patient questionnaire used as a screening tool and severity measure for generalized anxiety disorder. Both secondary measures have demonstrated good (PHQ-9; α ≥ 0.86 (29)) to excellent internal validity (GAD-7; α ≥ 0.92 (30)), and have been used previously in research involving individuals with brain injury (31) and their families (32,33).
Sociodemographic and Psychological Predictors of Seeking Health Information Online among GB2M in Ontario: Findings from the #iCruise Project
Published in International Journal of Sexual Health, 2022
David J. Brennan, Maya Kesler, Nathan J. Lachowsky, Adam Davies, Georgi Georgievski, Barry D. Adam, David Collict, Trevor A. Hart, Travis Salway, Dane Griffiths
We measured depressive symptoms using the Patient Health Questionnaire (PHQ-9) scale (Kroenke et al., 2001), one of the most widely validated depression measures. The PHQ-9 consists of 9 items and respondents are asked to indicate how often they have been bothered by various depressive symptoms in the past 2 weeks (0 = Not at all; 1 = Several days; 2 = More than half of the days; 3= Nearly every day). Responses of the 9-items were summed to generate a total score ranging from 0 to 27, with higher scores indicating higher degree of depressive symptoms. The internal reliability of the scale in the current sample was excellent (Cronbach’s alpha: 0.912). We used a previously established cutoff score to classify participants into “Moderate or Severe depression” (PHQ-9 ≥ 10) versus “Minimal or Mild depression” (PHQ-9 < 10).